Get started
Author

Owen A. Davis

Observed names: Davis, Owen A., Davis, Owen A.; Bull, James A.:, Davis, Owen Alexander, O. Davis, Owen A Davis, Owen Davis
ORCID: 0000-0002-7053-7079
Observed ORCID: 0000-0002-7053-7079
OpenAlex ID: A5075660331
Oxetanes: Recent Advances in Synthesis, Reactivity, and Medicinal Chemistry
2016 · James A. Bull, Rosemary A. Croft, et al. · Chemical Reviews · 501
Regio- and Stereospecific Synthesis of C-3 Functionalized Proline Derivatives by Palladium Catalyzed Directed C(sp3)–H Arylation
2014 · Dominic P. Affron, Owen A. Davis, et al. · Organic Letters · 150
PDF
Achieving In Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders
2020 · Benjamin R. Bellenie, Kwai-Ming J. Cheung, et al. · Journal of Medicinal Chemistry · 75
Synthesis of Di‐, Tri‐, and Tetrasubstituted Oxetanes by Rhodium‐Catalyzed OH Insertion and CC Bond‐Forming Cyclization
2014 · Owen A. Davis, James A. Bull · Angewandte Chemie International Edition · 71
PDF
Synthesis of diversely functionalised 2,2-disubstituted oxetanes: fragment motifs in new chemical space
2015 · Owen A. Davis, Rosemary A. Croft, et al. · Chemical Communications · 59
PDF
Recent Advances in the Synthesis of 2-Substituted Oxetanes
2015 · James Bull, Owen Davis · Synlett · 41
Copper-Catalyzed N-Arylation of 2-Imidazolines with Aryl Iodides
2013 · Owen A. Davis, Matthew Hughes, et al. · The Journal of Organic Chemistry · 27
Optimizing Shape Complementarity Enables the Discovery of Potent Tricyclic BCL6 Inhibitors
2022 · Owen A. Davis, Kwai-Ming J. Cheung, et al. · Journal of Medicinal Chemistry · 26
PDF
Synthesis of Substituted 1,4-Dioxenes through O–H Insertion and Cyclization Using Keto-Diazo Compounds
2016 · Owen A. Davis, Rosemary A. Croft, et al. · The Journal of Organic Chemistry · 20
Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 In Vivo
2022 · Rosemary Huckvale, Alice C. Harnden, et al. · Journal of Medicinal Chemistry · 19
Into Deep Water: Optimizing BCL6 Inhibitors by Growing into a Solvated Pocket
2021 · Matthew G. Lloyd, Rosemary Huckvale, et al. · Journal of Medicinal Chemistry · 18
Synthesis of Di‐, Tri‐, and Tetrasubstituted Oxetanes by Rhodium‐Catalyzed OH Insertion and CC Bond‐Forming Cyclization
2014 · Owen A. Davis, James A. Bull · Angewandte Chemie · 18
PDF
Discovery of an In Vivo Chemical Probe for BCL6 Inhibition by Optimization of Tricyclic Quinolinones
2023 · Alice C. Harnden, Owen A. Davis, et al. · Journal of Medicinal Chemistry · 12
PDF
Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays
2022 · Olivier A. Pierrat, Manjuan Liu, et al. · Scientific Reports · 8
PDF
Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapy
2025 · Eeson Rajendra, Claudio A Lademann, et al. · Nucleic Acids Research · 7
Fragment-Based Discovery and Structure-Led Optimization of MSC778, the First Potent, Selective, and Orally Bioavailable FEN1 Inhibitor
2025 · Sam E. Mann, Julien Lefranc, et al. · Journal of Medicinal Chemistry · 7
Discovery of ART5537: A Potent and Selective Small-Molecule Probe for EXO1
2025 · Sam E. Mann, Owen A. Davis, et al. · Journal of Medicinal Chemistry · 4
The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy
2026 · Helen M.R. Robinson, Vera Grinkevich, et al. · Clinical Cancer Research · 2
Data from The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy
2026 · Helen M.R. Robinson, Vera Grinkevich, et al.
Supplementary Data1 from The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy
2026 · Helen M.R. Robinson, Vera Grinkevich, et al.
Abstract 246: Discovery and mechanistic characterisation of the first oral bioavailable FEN1 inhibitor for treatment of HRD and EWS cancers and combination with various DDR inhibitors.
2026 · Lars T. Burgdorf, Julien Lefranc, et al. · Cancer Research
CCDC 2163947: Experimental Crystal Structure Determination
2022 · Huckvale, Rosemary, Harnden, Alice C., et al. · The Cambridge Structural Database
Improved binding affinity and pharmacokinetics enables sustained degradation of BCL6 in vivo
2022 · A. Harnden, R. Huckvale, et al. · European Journal of Cancer
ChemInform Abstract: Oxetanes: Recent Advances in Synthesis, Reactivity, and Medicinal Chemistry
2016 · James A. Bull, Rosemary A. Croft, et al. · ChemInform
Synthesis and functionalisation of highly substituted oxetanes: molecular scaffolds for drug discovery
2016 · Davis, Owen Alexander
Works count: 30
Citation count: 1,065
H-index: 12
I10-index: 13
Year
Topic
Type